Our research ranges from quick analyses of market movements and companies to comprehensive deep dives on therapeutic areas and companies. All pieces are grounded in data and designed to cut through industry noise. We also publish educational guides on how we perform our research and publish general news and opinions in the blog.
In-depth, data-driven analysis on biotech companies and markets.
Technical content, news, and opinions on the biotech industry.
Tutorials on biotech industry research methods and details about data sources and regulatory filings.
Duchenne muscular dystrophy has attracted an unusual concentration of specialist biotech hedge fund interest. We mapped interventional trials across 10 companies and overlaid beneficial ownership data from 18 specialist funds to show where that consensus sits and why.
Baker Bros filed Schedule 13D Amendment 17 on Acadia showing a renegotiated registration rights agreement allowing block trades. We pulled 14 years of Baker's 13D filing history to see what this could mean.
JPM Healthcare opening day triggers more biotech 8-K filings than any other day of the year. Analysis of SEC filing patterns shows 23% of public biotechs tracked by RxDataLab disclose on a single day.
Eight Wave Life Sciences executives adopted 10b5-1 trading plans in two clusters months apart, and all eight plans executed on the day of a clinical trial announcement.
How we use embeddings of clinical trial features to visualize and analyze the competitive biotech landscape.
Eikon Therapeutics has raised over $1B and claims to have a revolutionary drug discovery platform, but its clinical pipeline remains dominated by acquired oncology assets. This report analyzes Eikon’s funding, trials, and patent strategy to assess whether its platform is delivering.
After Lundbeck’s $2B acquisition of Longboard, investors scrambled for serotonin analogs. Here’s why Bright Minds was the target and what it says about the future of rare epilepsy drug development.
The FTC recently challenged over 100 Orange Book patent listings for drugs including blockbuster Ozempic. In fact, up to 89% of claimed patents were challenged for certain drugs. Here we dive into what was challenged, whether it matters, and what happens now.
RxDataLab
Get the data behind the analysis
We deliver primary-source biotech datasets for BD teams, investors, and the AI tools they're building. Tell us what you're tracking.
or email [email protected]